28.5.

2014 Overview of the therapy and prognosis of systemic lupus erythematosus in adults
http://www.uptodate.com.ezproxy.umf.ro/contents/overview-of-the-therapy-and-prognosis-of-systemic-lupus-erythematosus-in-adults?topicKey=RHEUM%2F467 1/22
Official reprint from UpToDate
www.uptodate.com 2014 UpToDate
Authors
Peter H Schur, MD
Daniel J Wallace, MD
Section Editor
David S Pisetsky, MD, PhD
Deputy Editor
Monica P Ramirez, MD, MPH
Overview of the therapy and prognosis of systemic lupus erythematosus in adults
All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Apr 2014. | This topic last updated: Sep 26, 2013.
INTRODUCTION Systemic lupus erythematosus (SLE) is a chronic, occasionally life-threatening, multisystem
disorder. Patients suffer from a wide array of symptoms and have a variable prognosis that depends upon the
severity and type of organ involvement. The diagnosis of SLE should be confirmed prior to initiating treatment (table
1). (See "Diagnosis and differential diagnosis of systemic lupus erythematosus in adults".)
Due to the uncertain course, effective treatment requires ongoing patient-doctor communication to correctly
interpret laboratory tests, to alleviate symptoms, to prevent and treat relapses, to lessen side effects related to drug
therapy, to improve adherence with medications, and to coordinate care with the patients primary care provider [1-
6].
This topic will review the general issues related to the treatment and prognosis of patients with SLE. The treatment
of specific organ involvement is discussed separately. (See appropriate topic reviews.)
DETERMINATION OF DISEASE ACTIVITY AND SEVERITY An effective therapeutic regimen first requires
confirmation of the diagnosis and the accurate determination of both disease activity and severity [7-11]. Disease
activity usually refers to the degree of inflammation, while the degree of severity depends upon the level of organ
dysfunction and upon the organs relative importance. The degree of irreversible organ dysfunction has been referred
to as the damage index [12].
The presence of severe organ dysfunction does not necessarily imply ongoing inflammation. As an example,
marked proteinuria and a decreasing glomerular filtration rate may result either from active inflammation or from
scarred nephrons in the absence of active inflammatory disease. The ability to differentiate between these two
possibilities is extremely important, since immunosuppressive therapy is not indicated in the latter setting. (See
"Therapy of diffuse or focal proliferative lupus nephritis".)
Clinically useful markers of activity Disease activity is assessed using a combination of the clinical history,
physical examination, organ-specific functional tests, and serologic studies [7-11,13-15]. Examples include:

Active systemic lupus erythematosus (SLE) (particularly lupus nephritis) is often preceded by a rise in
immunoglobulin G (IgG) anti-double-stranded deoxyribonucleic acid (dsDNA) titers [16-20], by a fall in
complement levels (especially CH50, C3, and C4) [17,19,20], and by an elevation in complement split and
activation products [17,19-21].

Persistently low serum levels of complement C1q are associated with continued activity of proliferative
glomerulonephritis [22].

Increases in the erythrocyte sedimentation rate (ESR) and in the serum C-reactive protein (CRP)
concentration are also commonly seen within this setting [23-26], and, in one study, increases in the CRP
were associated with a broad range of particular clinical features and with disease activity or organ damage in
certain systems [27]. The association of increased CRP with disease activity was noted particularly with
constitutional, eye, pulmonary, gastrointestinal, and neurologic disease activity, but elevated CRP was not

28.5.2014 Overview of the therapy and prognosis of systemic lupus erythematosus in adults
http://www.uptodate.com.ezproxy.umf.ro/contents/overview-of-the-therapy-and-prognosis-of-systemic-lupus-erythematosus-in-adults?topicKey=RHEUM%2F467 2/22
However, not all patients with these serologic markers have active disease, and these markers do not necessarily
predict disease exacerbation or flares (see 'Definition of flares' below) [25] . In one study, for example, 12 percent
of patients with hypocomplementemia and elevated anti-DNA antibody titers had no clinical evidence of active
disease [30]. We favor an approach in which such patients are closely monitored; therapy is adjusted if there are
signs of clinical worsening of the disease.
Definition of flares The clinical course of SLE is variable and may be characterized by unpredictable disease
flares and remissions. There is no consensus on what constitutes a disease flare, but most definitions have
incorporated a combination of results from serologic measures and disease activity indices. Flares are generally
qualified by severity, with moderate or severe flares being the most clinically significant. Most clinicians agree that
a moderate or severe flare refers to a measurable increase in disease activity that is clinically meaningful enough to
result in a change in therapy [31-33]. A challenge in clinical practice is to stratify patients at risk for disease flares.
We use serologic measures of disease activity in the context of the clinical presentation and organ domain
involvement to evaluate for a disease flare. (See 'Clinically useful markers of activity' above.)
Frequency of laboratory testing The frequency with which monitoring laboratory tests are performed is tailored
to each patient. In general, patients with more active disease are monitored more frequently, while those with
inactive disease require less frequent monitoring. As examples:
The following laboratory tests are suggested for monitoring in a patient with a previous history of renal involvement
who is currently free of proteinuria and who has a normal creatinine clearance:
For patients without a history of lupus nephritis, the spot (untimed) urine protein and creatinine, as well as the
serum albumin, are unnecessary.
Investigational markers Numerous investigations of other immunologic tests as indicators of disease activity
have been reported, including antibodies to C1q and to nucleosomes, complement activation products, soluble T-
cell activation markers, serum levels of various cytokines and cytokine receptors, angiogenic factors, adhesion
molecules, chemokines, and cell surface makers of immunologic activation (eg, erythrocyte- or reticulocyte-bound
associated with an index of organ damage [28]. There are conflicting data on the diagnostic value of a marked
elevation of CRP in distinguishing active lupus from infection [24,29], but a markedly elevated level of CRP in a
patient with SLE should raise the suspicion for infection [26].
A patient with active lupus nephritis may have a battery of tests done once weekly.
For someone with a reduction in glomerular filtration rate whose disease is stable and who is free of
proteinuria, testing every two to three months may be appropriate.

A patient with previously active nephritis, a normal glomerular filtration rate, and no proteinuria, whose SLE is
otherwise quiescent, may be tested every four to six months.

Someone with no history of renal involvement and with quiescent disease may be retested every 6 to 12
months.

Complete blood count

Erythrocyte sedimentation rate
C-reactive protein
Urinalysis with examination of urinary sediment
Spot (untimed) urine protein and creatinine
Serum creatinine and estimated glomerular filtration rate (eGFR)
Serum albumin
Anti-dsDNA
Complement (CH50, C3, and C4)
28.5.2014 Overview of the therapy and prognosis of systemic lupus erythematosus in adults
http://www.uptodate.com.ezproxy.umf.ro/contents/overview-of-the-therapy-and-prognosis-of-systemic-lupus-erythematosus-in-adults?topicKey=RHEUM%2F467 3/22
C4d) [20].
Gene expression profiling and proteomic approaches may eventually provide additional indices of disease activity.
As examples:
The usefulness of the investigational markers of disease activity noted above either has been unconfirmed or has
generally not been proven to be as useful as monitoring complement and anti-double stranded DNA antibodies.
Disease activity indices A number of research protocol disease activity or damage measures or indices,
including the Systemic Lupus Erythematosus (SLE) Disease Activity Index (SLEDAI), the Safety of Estrogens in
Lupus Erythematosus: National Assessment-SLEDAI (SELENA-SLEDAI), the Systemic Lupus Activity Measure
(SLAM), the British Isles Lupus Assessment Group (BILAG), the European Consensus Lupus Activity
Measurement (ECLAM), and others, have been designed in an attempt to better monitor disease activity and to
assess trial outcomes [15,38,41-46]. They all use a combination of history, examination, and laboratory data; these
protocols may have general applicability to clinical practice if simplified. The particular outcome measure used in a
trial, even for organ-specific disease such as lupus nephritis, can influence apparent trial outcomes [47].
Clinical trials are also using combinations of indices to create composite assessment measures for determining
trial outcomes. Examples include the SRI (Systemic Lupus Erythematosus Response Index), used in the pivotal
belimumab trials, and the BICLA (BILAG-based Combined Lupus Assessment), used in a trial of epratuzumab [48].
(See 'Belimumab' below.)
GENERAL TREATMENT CONSIDERATIONS Although the pattern and severity of organ involvement determines
specific drug therapy, a number of general issues are applicable to every patient with systemic lupus
erythematosus (SLE). We emphasize the importance of adherence to medication regimens, of maintenance of
good sleep hygiene, and of follow-through with recommended testing. Patients should also be informed of the
availability of resource information relating to the treating center and to lupus support organizations [6,49].
Sun protection Avoid exposure to direct or reflected sunlight and other sources of ultraviolet (UV) light (eg,
fluorescent and halogen lights). Use sunscreens, preferably those that block both UV-A and UV-B, with a high skin
protection factor (SPF). A sunscreen with a SPF of 55 or greater is suggested.
Diet and nutrition Limited data exist concerning the effect of dietary modification in SLE [50,51]. Of two studies
performed by one group of investigators, the larger trial randomly assigned 60 patients to receive either 1.8 g of
eicosapentaenoic acid (EPA) and 1.2 g of docosahexanoic acid (DHA) or placebo, daily, for 24 weeks [51]. Those
on fish oil had a significantly greater reduction in an index of disease activity (the revised SLAM [SLAM-R]) and
improvement in endothelial function, as assessed by flow-mediated arterial dilation, than did the placebo group.
These findings await independent confirmation; thus, we do not recommend fish oil supplements in the treatment of
SLE.
A conservative approach is to recommend a balanced diet consisting of carbohydrates, proteins, and fats. However,
An increased expression of genes activated by interferon in peripheral blood mononuclear cells has been
noted [34,35].

Active disease may be associated with a constellation of autoantibodies that can be detected using
glomerular proteomic arrays [36].

A proteomic approach identified a pattern of proteins that was both sensitive and specific for active nephritis
[37].

Increased amounts of erythrocyte-bound C4d were correlated with increased disease activity in one study [38]
but not in another [39].

Urinary biomarkers for nephritis include interleukin-6, neutrophil gelatinase-associated lipocalin, monocyte
chemoattractant protein, micro-ribonucleic acid (miRNA), and transforming growth factor- [39,40]

28.5.2014 Overview of the therapy and prognosis of systemic lupus erythematosus in adults
http://www.uptodate.com.ezproxy.umf.ro/contents/overview-of-the-therapy-and-prognosis-of-systemic-lupus-erythematosus-in-adults?topicKey=RHEUM%2F467 4/22
the diet should be modified based upon disease activity and upon the response to therapy:
Exercise Inactivity produced by acute illness causes a rapid loss of muscle mass, bone demineralization, and
loss of stamina resulting in a sense of fatigue. This can usually be treated with isometric and graded exercise
[57,58]. In selected refractory cases, relief can be obtained with antimalarial drugs [59].
Smoking cessation Cigarette smoking may increase the risk of developing SLE [60], and smokers in general
have more active disease [61]. Patients should be counseled not to smoke or to quit smoking and should be
provided with help to do so. Hydroxychloroquine is less effective in smokers [61,62]. (See "Patient information:
Quitting smoking (Beyond the Basics)" and "Overview of smoking cessation management in adults".)
Immunizations We advise that patients should receive appropriate immunizations prior to the institution of
immunosuppressive therapies. It had been previously thought that immunization could exacerbate SLE. However,
influenza vaccine and pneumococcal vaccines are safe, but resultant antibody titers are somewhat less in patients
with SLE than in controls [63,64]. The quadrivalent human papilloma virus (HPV) vaccine has also been shown to
be safe and reasonably effective in patients with stable SLE, without increasing disease activity or flares [65]. Use
of glucocorticoids, such as prednisone, or other immunosuppressive agents may contribute to the blunted antibody
response. (See "Glucocorticoid effects on the immune system", section on 'Impact on vaccination'.)
In contrast, it is inadvisable to immunize potentially immunosuppressed patients (including those treated with
glucocorticoids alone at doses equivalent to 20 mg/day of prednisone for more than two weeks) with live vaccines
(eg, measles, mumps, rubella, polio, varicella, and vaccinia [smallpox]) [63]. (See "Immunizations in patients with
Patients with active inflammatory disease and fever may require an increase in caloric intake.
Glucocorticoids enhance appetite, resulting in potentially significant weight gain. Hunger can be somewhat
lessened by the ingestion of water, antacids, proton pump inhibitors, and/or histamine H2 blockers. A low
calorie diet should be instituted if there is significant weight gain.

Hyperlipidemia may be induced by the nephrotic syndrome or by the administration of glucocorticoids (see
"Lipid abnormalities in nephrotic syndrome") [52] . In one report, increasing the dose of prednisone by 10 mg
per day was associated with an elevation in serum cholesterol of 7.5 mg/dL (0.2 mmol/L) [53].
Patients with hyperlipidemia should be encouraged to eat a low-fat diet [54]. A lipid-lowering agent (usually a
statin) should be considered if serum cholesterol remains above the recommended values despite a change in
diet. (See "Treatment of lipids (including hypercholesterolemia) in primary prevention".)

Vitamins are rarely needed when patients eat a balanced diet. However, a daily multivitamin should be taken
by patients who are not able to obtain an adequate diet or who are dieting to lose weight.

The majority of patients with SLE have low serum levels of 25-hydroxyvitamin D (calcidiol) [55], probably due,
at least in part, to avoidance of sun exposure. Patients with low vitamin D levels should be treated with
supplemental vitamin D. (See "Musculoskeletal manifestations of systemic lupus erythematosus".)
Patients on long-term glucocorticoids and postmenopausal women should ingest 800 units of vitamin D plus
1500 mg of calcium per day and/or should ingest a bisphosphonate to minimize the degree of bone loss. (See
"Prevention and treatment of glucocorticoid-induced osteoporosis".)

Herbal remedies are of unproven benefit and may cause harm [56].
In patients with hypertension and/or nephritis, dietary measures such as salt restriction may be required. (See
"Salt intake, salt restriction, and primary (essential) hypertension" and "Diet in the treatment and prevention of
hypertension".)

In patients who are overweight, measures to encourage weight loss should be instituted. (See "Overview of
therapy for obesity in adults".)

28.5.2014 Overview of the therapy and prognosis of systemic lupus erythematosus in adults
http://www.uptodate.com.ezproxy.umf.ro/contents/overview-of-the-therapy-and-prognosis-of-systemic-lupus-erythematosus-in-adults?topicKey=RHEUM%2F467 5/22
cancer".)
While the issue of efficacy of vaccination with hepatitis B (HepB) vaccine has not been completely resolved, the
risks posed by HepB vaccine to patients with SLE must, at most, be very small [63,66].
Prophylaxis for Pneumocystis pneumonia is discussed elsewhere. (See "Treatment and prevention of
Pneumocystis pneumonia in non-HIV-infected patients", section on 'Systemic lupus erythematosus'.)
Radiation therapy Anecdotal reports of increased toxicity following therapeutic ionizing radiation have made
radiation oncologists wary of treating patients with SLE and other collagen vascular disorders [67]. Patients with
scleroderma may be at greater risk. However, if needed, radiation therapy may be used in patients with SLE to treat
malignant disease.
Among the studies and reviews that have addressed the safety and toxicity of radiation therapy in patients with SLE
[49,68-71] the following are illustrative:
Patients who have an overlap of scleroderma with SLE appear to be at highest risk of marked fibrotic reaction to
radiation therapy.
Treating comorbid conditions Accelerated atherosclerosis, pulmonary hypertension, and antiphospholipid
antibodies, as well as osteopenia or osteoporosis, are among the comorbid conditions which can be treated and for
which screening tests are appropriately used. These comorbid disorders, for which patients with SLE have an
increased risk, include [6]:
Avoidance of specific medications Some data suggest that sulfonamide-containing antibiotics (eg,
sulfadiazine, trimethoprim-sulfamethoxazole, sulfisoxazole) may cause exacerbations and should, therefore, be
avoided [72]. This impression with regard to sulfa-containing agents was supported by the following:
In contrast, medications that cause drug-induced lupus, such as procainamide and hydralazine, do not cause
exacerbations of idiopathic SLE. This observation is a presumed reflection of the pathogenetic differences between
Two observational series have included 19 patients with SLE among those with collagen vascular diseases
receiving radiation therapy for cancer [68,69]. No unusually severe local reactions in the skin or subcutaneous
tissues in the radiation portal were noted in those with lupus.

One study included 17 patients with SLE who received radiation therapy [49]. Four patients had a grade 3 or
higher toxicity at 5 to 10 years. There was a trend toward greater toxicity with more severe disease and with
more extensive organ involvement.

Accelerated atherosclerosis (see "Coronary heart disease in systemic lupus erythematosus", section on
'Prevention and treatment')

Pulmonary hypertension Although an imperfect screening test, Doppler echocardiography is usually used as
the initial noninvasive study for pulmonary hypertension. (See "Clinical features and diagnosis of pulmonary
hypertension in adults".)

Antiphospholipid antibodies The presence of antiphospholipid antibodies is assessed by assays for

antibodies to cardiolipin (aCL), for antibodies to beta 2 glycoprotein-1 (anti-2 glycoprotein-I), and for the
presence of lupus anticoagulant (LA) activity. (See "Diagnosis of the antiphospholipid syndrome".)

Osteopenia or osteoporosis Bone mineral density determination may detect the presence of osteopenia or
osteoporosis and may allow dietary or medical interventions to prevent or reverse bone demineralization. (See
"Screening for osteoporosis".)

A case-control study of 145 patients with SLE and 104 controls, in which adverse reactions to sulfonamide-
containing antibiotics were more than twice as frequent in those with SLE (52 versus 19 percent) [73]

A study of 417 patients with SLE, among whom 114 (27 percent) had a history of sulfonamide allergy [74]
28.5.2014 Overview of the therapy and prognosis of systemic lupus erythematosus in adults
http://www.uptodate.com.ezproxy.umf.ro/contents/overview-of-the-therapy-and-prognosis-of-systemic-lupus-erythematosus-in-adults?topicKey=RHEUM%2F467 6/22
the two disorders. (See "Drug-induced lupus".)
Minocycline can also cause drug-induced lupus. We advise against its use in patients with SLE. (See "Drug-
induced lupus", section on 'Overview of causative drugs' and "Drug-induced lupus".)
Pregnancy and contraception Pregnancy should be avoided during active disease (especially with significant
organ impairment) due to the high risk of miscarriage and exacerbation of SLE. Women with SLE should be
counseled not to become pregnant until the disease has been quiescent for at least six months. (See "Pregnancy
in women with systemic lupus erythematosus".)
Oral contraceptives containing high-dose estrogens can cause exacerbations of SLE. However, this complication
rarely occurs with the current use of low-dose estrogen or progesterone-containing compounds. Patients with
migraine headaches, Raynaud phenomenon, a history of phlebitis, or antiphospholipid antibodies probably should
not be treated with oral contraceptives. Hormone replacement therapy in postmenopausal women may be
associated with a modest increase in the rate of flares, and decisions about use of estrogen for postmenopausal
symptoms must be carefully considered weighing the potential benefits against risks of thrombotic events and of
breast and uterine cancer [75]. (See "Menstrual function, menopause, and hormonal contraceptives in women with
systemic lupus erythematosus".)
Pregnant patients with active lupus are generally managed with glucocorticoids. Other drugs used during pregnancy
include nonsteroidal antiinflammatory drugs (avoided during early pregnancy and in the third trimester) and
hydroxychloroquine (probably safe). Cyclophosphamide, cyclosporine, mycophenolate mofetil, and methotrexate
are contraindicated, while azathioprine can be cautiously used. (See "Pregnancy in women with systemic lupus
erythematosus" and "Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during
pregnancy and lactation".)
TREATMENT OF SPECIFIC ORGAN INVOLVEMENT A number of medications are commonly used in the
treatment of systemic lupus erythematosus (SLE), including nonsteroidal antiinflammatory drugs (NSAIDs),
antimalarials (primarily hydroxychloroquine), glucocorticoids, and immunosuppressive agents (including
cyclophosphamide, cyclosporine, tacrolimus, leflunomide, methotrexate, azathioprine, mycophenolate, and
belimumab). Patient compliance with recommended treatment is, as expected, associated with better outcomes
than noncompliance [76].
What follows is a general overview of which drugs are preferred in selected clinical settings:
Topical therapies are often useful for cutaneous manifestations of lupus and reduce the risk of side effects that
are associated with systemic use of NSAIDs, glucocorticoids, or immunosuppressants.

NSAIDs are generally effective for musculoskeletal complaints, fever, headaches, and mild serositis.
Naproxen may have greater relative cardiovascular safety than other NSAIDs. Celecoxib has been used in
SLE patients, even in those with sulfa allergy, without precipitating any allergic response but should be
administered with caution [77]. (See "Musculoskeletal manifestations of systemic lupus erythematosus" and
"Overview of selective COX-2 inhibitors", section on 'Sulfonamide allergy'.)

Antimalarials are most useful for skin manifestations and for musculoskeletal complaints. In addition, in long-
term studies, the use of antimalarials, such as hydroxychloroquine, prevented major damage to the kidneys
and central nervous system [78,79]. Their use may also reduce the risk of disease flares, though this is less
clear for renal and central nervous system (CNS) manifestations [80]. Antimalarials and their use in SLE are
discussed in detail elsewhere. (See "Mucocutaneous manifestations of systemic lupus erythematosus" and
"Antimalarial drugs in the treatment of rheumatic disease".)

Systemic glucocorticoids (eg, high doses of 1 to 2 mg/kg/day of prednisone or equivalent or intermittent

intravenous pulses of methylprednisolone) used alone or in combination with immunosuppressive agents are
generally reserved for patients with significant organ involvement, particularly renal and CNS disease. There is
a paucity of data to support the use of intravenous pulse versus daily oral glucocorticoids [81]. Patients with

28.5.2014 Overview of the therapy and prognosis of systemic lupus erythematosus in adults
http://www.uptodate.com.ezproxy.umf.ro/contents/overview-of-the-therapy-and-prognosis-of-systemic-lupus-erythematosus-in-adults?topicKey=RHEUM%2F467 7/22
OTHER THERAPIES Several types of agents have been used in patients resistant to more well-established
therapeutic approaches, including biologic agents that target either B cells or T cells.
Patients with severe organ involvement who are resistant to cyclophosphamide therapy generally do poorly. The
optimal approach to such patients is uncertain. (See "Therapy of diffuse or focal proliferative lupus nephritis".)
Belimumab Belimumab (Benlysta, formerly termed Lymphostat-B) is a fully human monoclonal antibody that
inhibits the biologic activity of the soluble form of a B-cell survival factor, B-lymphocyte stimulator or BLyS (also
known as B-cell activating factor belonging to the tumor necrosis factor [TNF] family [BAFF]); belimumab has
become available in the United States for the treatment of patients with active autoantibody-positive systemic lupus
organ-threatening disease (eg, cardiopulmonary, hepatic, renal, hemolytic anemia, immune
thrombocytopenia) are usually given the above-mentioned oral doses, whereas non-organ-threatening disease
(eg, cutaneous, musculoskeletal, constitutional) patients usually respond to 5 to 15 mg of prednisone (or
equivalent) daily until a glucocorticoid-sparing agent or antimalarial can take effect.
Immunosuppressive medications other than glucocorticoids (eg, methotrexate [82], cyclophosphamide,
azathioprine, mycophenolate, or rituximab) are generally reserved for patients with significant organ
involvement and/or for patients who have had an inadequate response to glucocorticoids. The use of
cyclophosphamide and other immunosuppressive agents in SLE is discussed in greater detail elsewhere.
(See "Therapy of diffuse or focal proliferative lupus nephritis" and "Clinical features and therapy of
membranous lupus nephritis" and "Therapy of resistant or relapsing diffuse or focal proliferative lupus
nephritis" and "Neurologic manifestations of systemic lupus erythematosus" and "Mucocutaneous
manifestations of systemic lupus erythematosus" and "Systemic lupus erythematosus in children: Pulmonary
manifestations" and "Gastrointestinal manifestations of systemic lupus erythematosus" and "Pulmonary
manifestations of systemic lupus erythematosus in adults" and "Management of refractory discoid lupus and
subacute cutaneous lupus" and "Hematologic manifestations of systemic lupus erythematosus in adults" and
"Non-coronary cardiac manifestations of systemic lupus erythematosus in adults" and "Neuropsychiatric
manifestations of systemic lupus erythematosus".)
Immunosuppressive agents such as mycophenolate, azathioprine, or cyclophosphamide are given with
glucocorticoids to patients with more than mild lupus nephritis, and cyclophosphamide is given to those with
alveolar hemorrhage, to those with systemic vasculitis, and to most patients with significant CNS involvement.
Lower doses of glucocorticoids (eg, 10 mg/day of prednisone) may be used for symptomatic relief of severe
arthralgia, arthritis, or serositis while awaiting a therapeutic effect from other medications. (See "Therapy of
diffuse or focal proliferative lupus nephritis" and "Neurologic manifestations of systemic lupus erythematosus"
and "Pulmonary manifestations of systemic lupus erythematosus in adults".)

Belimumab is available in the United States for the treatment of patients with active SLE who are receiving
standard therapy, such as NSAIDs, glucocorticoids, antimalarials, and/or immunosuppressives [83]. However,
it has not been adequately studied in patients with severe active lupus nephritis or with CNS lupus or in
patients who have previously used rituximab or who have recently used intravenous cyclophosphamide. The
role of belimumab in SLE treatment is uncertain. (See 'Belimumab' below.)

Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEA sulfate) are major circulating
androgens, and dietary supplements containing these androgenic steroids are widely available (see
"Dehydroepiandrosterone and its sulfate"). Women with systemic lupus erythematosus have low serum DHEA
and DHEA sulfate concentrations, even prior to initiating chronic glucocorticoid therapy [84]. A 2007 meta-
analysis concluded that DHEA probably leads to little or no important difference in disease activity in people
with mild to moderate SLE; it may improve overall well being but does so at the expense of androgenic side
effects including acne, hair growth, and menstrual changes [85]. In addition, because the purity and potency
of available dietary supplements are uncontrolled, use of DHEA or DHEA sulfate supplements is not
recommended.

28.5.2014 Overview of the therapy and prognosis of systemic lupus erythematosus in adults
http://www.uptodate.com.ezproxy.umf.ro/contents/overview-of-the-therapy-and-prognosis-of-systemic-lupus-erythematosus-in-adults?topicKey=RHEUM%2F467 8/22
erythematosus (SLE) who are receiving standard therapy, including NSAIDs, glucocorticoids, antimalarials, or
immunosuppressives [83,86-90]. It has not been evaluated in patients with severe active lupus nephritis or with
severe active central nervous system lupus, nor has it been studied in combination with other biologics or
intravenous cyclophosphamide. Also, the use of belimumab is not recommended by the manufacturer in these
situations [91]. However, the role of belimumab in SLE treatment is evolving. (See "The humoral immune response",
section on 'TACI, BAFF and APRIL'.)
Based upon the available data and upon our clinical experience, we suggest limiting the use of belimumab to
patients who are similar to those enrolled in the two major trials, such as those with active musculoskeletal or
cutaneous disease. The dose regimen recommended by the manufacturer is 10 mg/kg at two-week intervals for the
first three doses and at four-week intervals thereafter.
We advise limiting its use to patients who require at least 10 mg daily of prednisone along with antimalarials and
with azathioprine, mycophenolate, or methotrexate to maintain control of disease activity or to patients who are
intolerant of such medications. We do not recommend its use for the purpose of treating severe active lupus
nephritis or severe active central nervous system (CNS) lupus until efficacy has been shown for these indications.
Live vaccines should not be given concurrently with belimumab.
Levels of BLyS are elevated in some patients with SLE, and it may play a role in the pathogenesis of lupus by
promoting the formation and survival of memory B cells and plasmablasts making autoantibodies. Inhibition of BLyS
can reduce the numbers of B cells and short-lived plasma cells and can decrease anti-double stranded DNA
antibody titers [86]. (See "Epidemiology and pathogenesis of systemic lupus erythematosus", section on 'Immune
abnormalities'.)
Two randomized, multinational trials (the BLISS-52 trial and BLISS-76 trial) involving a total of 1684 patients
demonstrated the efficacy and safety of belimumab [87,88]. In the BLISS-52 trial, 867 patients with active lupus and
with a positive antinuclear antibody (ANA) or anti-double-stranded DNA antibody were randomly assigned to receive
belimumab 10 mg/kg or 1 mg/kg (administered intravenously on days 0, 14, and 28 and every 28 days until 48
weeks) or placebo infusions, together with their standard care, including NSAIDs, antimalarials, glucocorticoids,
and immunosuppressives [87]. Outcomes were assessed with a novel endpoint, the SLE responder index (SRI),
which was developed based upon a retrospective analysis of data from an earlier randomized trial of belimumab
[92]. Patients were defined as responders based upon the following:
A significantly higher likelihood of achieving an SRI at one year was observed with belimumab (10 or 1 mg/kg)
compared with placebo (58 and 51 percent versus 44 percent, odds ratios (OR) 1.83, 95% CI 1.3-2.59, and 1.55,
95% CI 1.1-2.19, respectively). Additionally, belimumab was glucocorticoid-sparing. Those with a baseline dose of
prednisone greater than 7.5 mg/day who received belimumab were significantly more likely, compared with patients
receiving placebo, to experience a sustained reduction in glucocorticoid doses (28 and 24 percent versus 15
percent, OR 1.96, 95% CI 1.25-3.07, and 1.6, 95% CI 1.01-2.53, respectively).
Similar but more modest benefit was described at 52 weeks in a preliminary report of the other large randomized
trial (BLISS-76), although, at 76 weeks, the degree of benefit was no longer statistically significant [88,89].
The overall adverse event rates were similar in the patients receiving belimumab (10 or 1 mg/kg) or placebo in the
Overall improvement in disease activity of at least four points on the SLE Disease Activity Index (SLEDAI) as
modified for the Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) trial (the
SELENA-SLEDAI) [46]

A lack of significant disease progression in any single dimension or organ system, as indicated by the
absence of a new British Isles Lupus Assessment Group (BILAG) A organ domain score and by no more than
one new BILAG B organ domain score [93,94]

No worsening (less than a 0.3 out of 3 increase) in the Physicians Global Assessment (PGA) compared with
baseline [46]

28.5.2014 Overview of the therapy and prognosis of systemic lupus erythematosus in adults
http://www.uptodate.com.ezproxy.umf.ro/contents/overview-of-the-therapy-and-prognosis-of-systemic-lupus-erythematosus-in-adults?topicKey=RHEUM%2F467 9/22
published BLISS-52 trial, including serious infections, which were seen in 4 to 8 percent of patients. However, the
FDA reported that, during all clinical studies and trials of the drug, more deaths and serious infections occurred with
belimumab compared with placebo [83]. Severe or serious hypersensitivity reactions were seen on infusion days in
two patients in each belimumab group (less than 1 percent) but in none of the patients receiving placebo in the
BLISS-52 trial. The most common adverse reactions in the clinical trials (occurring in at least 5 percent of patients)
were nausea, diarrhea, and fever. Nasopharyngitis, bronchitis, insomnia, pain in the extremities, depression,
migraine, and pharyngitis were also commonly reported.
Post hoc analyses have further examined the results of these trials [95-98]. Reported benefits include less active
disease, improved laboratory parameters, decreased musculoskeletal and mucocutaneous involvement,
improvements in health quality of life outcomes, and decreased requirements for glucocorticoids.
There are several limitations to the available data regarding the benefits of belimumab in SLE:
Thus, further studies are required to define the clinical utility of belimumab.
Rituximab Monoclonal anti-B lymphocyte antibodies may be beneficial for patients with disease that is
resistant to other therapy [99]. However, concern has arisen from case reports of a possible association of the use
of the chimeric anti-CD20 monoclonal antibody agent, rituximab, with fatal progressive multifocal
leukoencephalopathy (PML) due to reactivation of latent infection with the JC virus; such reports in two patients with
SLE caused the United States Food and Drug Administration (FDA) to issue an alert to health providers [100,101].
Both patients had received other immunosuppressive therapies. Other case reports of PML in patients treated for
other diseases with rituximab [101-105] suggest that B-cell depleting therapies should be used cautiously. (See
"Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections" and "Progressive multifocal
leukoencephalopathy: Prognosis and treatment".)
Rituximab, cyclophosphamide, and glucocorticoids The combination of the B-cell depleting chimeric
monoclonal antibody rituximab, cyclophosphamide, and high-dose glucocorticoids, as used in the treatment of
lymphoma, has shown some promise in uncontrolled, observational studies [106-109]. The potential benefits and
adverse effects were illustrated in a large study of this combination in 90 patients with SLE refractory to
conventional treatment [107]. Following rituximab infusion, patients were followed for 3 to 40 months. A meaningful
decrease in disease activity was noted in 80 percent, and infusions were well-tolerated in 90 percent of patients.
However, adverse events (ascribed to hypersensitivity to the chimeric antibody) occurred in 10 percent.
Rituximab without cyclophosphamide Despite promising reports from uncontrolled studies [110-113], a
placebo-controlled, randomized trial of 257 patients with active SLE (EXPLORER trial), which excluded those with
nephritis, noted no significant difference in outcomes between those who received prednisone plus two infusions of
rituximab and those who received prednisone plus placebo infusions [114].
Improvement in lupus nephritis following rituximab treatment was noted in a series of 10 patients; five achieved a
complete remission a median of three months after beginning rituximab treatment [115]. Eight patients experienced
partial remissions at a median of two months. However, a large randomized study with a similar design to
EXPLORER of rituximab in patients with lupus nephritis (LUNAR trial) was not successful [116]. This may have
The subset of patients of African heritage and of African-Americans in the two major trials did not respond to
treatment with belimumab, although insufficient numbers of such patients were enrolled to draw definite
conclusions; additional studies in this population will be performed [83].

Patients who had received prior B-cell targeted therapy, such as rituximab, or who had received intravenous
cyclophosphamide within the preceding six months were excluded from the trials.

Belimumab has not been compared with any other active therapeutic agent used in the treatment of SLE, nor
has it been studied in combination with other biologic agents or with cyclophosphamide.

Patients with severe active lupus nephritis or severe active CNS lupus were excluded from the trials.
28.5.2014 Overview of the therapy and prognosis of systemic lupus erythematosus in adults
http://www.uptodate.com.ezproxy.umf.ro/contents/overview-of-the-therapy-and-prognosis-of-systemic-lupus-erythematosus-in-adults?topicKey=RHEUM%2F46 10/22
been due to patients in both study arms having been given highly effective therapy with large doses of
glucocorticoids and immunosuppressive agents, and the open label extension part of the protocol was halted due to
concern relating to PML.
Hematopoietic stem cell transplantation The proposed mechanism of action of hematopoietic stem cell
transplantation is that it provides a period free from memory T-cell influence, during which maturation of new
lymphocyte progenitors can occur without recruitment to anti-self activity. (See "The adaptive cellular immune
response", section on 'Memory T cells'.)
Results from this approach are limited and include:
Autologous stem cell transplantation remains complex, costly, and, despite improvements in treatment-related
mortality, risky. Additional study, including direct comparison with more conventional treatment approaches in
randomized controlled trials, is needed before any recommendation can be made regarding the role of stem cell
transplantation in the treatment of SLE. Use of allogenic stem cells is an interesting alternative for which there are
insufficient data to assess efficacy or safety.
Immunoablation alone Immunoablation without bone marrow or stem cell support has also been effective in
some patients with moderate to severe SLE refractory to glucocorticoids and immunosuppressive therapy [119].
However, safety concerns caused the US National Institutes of Health to halt their trial that was examining the
effectiveness of immunoablation alone.
Cyclosporine Cyclosporine (or ciclosporin) inhibits the transcription process that is normally associated with T-
cell activation (see "Pharmacology and side effects of cyclosporine and tacrolimus", section on 'Mechanism of
action'). Addition of cyclosporine may allow a reduction in the use of glucocorticoids. As an example, an unblinded
study randomly assigned 89 patients with SLE, who were taking 15 mg of prednisolone per day and who required
the addition or change of a glucocorticoid-sparing drug, to receive either cyclosporine or azathioprine [120].
Both cyclosporine and azathioprine allowed reduction in prednisolone dose at the end of one year of study. There
was no statistically significant difference between cyclosporine and azathioprine in the reduction in dose (mean
decrease in daily prednisolone dose of 9 mg and 10.7 mg, respectively, a difference of -1.7 mg [95% CI -4.4 to
+0.9]).
Similar rates of study drug discontinuation were noted for each group. Discontinuations due to lack of efficacy and
due to side effects were also similar. In this study, neither severe hypertension nor irreversible renal injury occurred
in the cyclosporine-treated subjects. However, hypertension was noted more frequently in patients who received
cyclosporine (49 versus 14 percent), as was an increase in the serum creatinine (13 versus 2 percent). When
cyclosporine is used in clinical practice, these side effects must be anticipated. Frequent monitoring of blood
pressure and renal function is necessary for appropriate dose titration. (See "Cyclosporine and tacrolimus
nephrotoxicity".)
Other agents in clinical trials A number of other therapeutic approaches have been tried or are under
investigation in SLE, some of which are available for use in other immune-mediated conditions including rheumatoid
arthritis. These include intravenous immunoglobulin; thalidomide; zileuton; sirolimus; eculizimab; anti-interleukin
High-dose chemotherapy followed by autologous stem cell transplantation administered to 50 patients with
glomerulonephritis, cerebritis, transverse myelitis, autoimmune cytopenia, catastrophic antiphospholipid
syndrome, and/or vasculitis despite intravenous cyclophosphamide [117]. The overall five-year survival was 84
percent, and the probability of disease survival at five years was 50 percent. Treatment related mortality, in an
intention to treat analysis, was 4 percent.

Results from the European Registry of autologous stem cell transplantation for SLE, which were notable for
induction of remission of disease activity in 33 of 50 cases [118]. However, one-third of the patients relapsed
at a median of six months. Survival was 62 percent at 48 months, with a treatment-related mortality of 12
percent.

28.5.2014 Overview of the therapy and prognosis of systemic lupus erythematosus in adults
http://www.uptodate.com.ezproxy.umf.ro/contents/overview-of-the-therapy-and-prognosis-of-systemic-lupus-erythematosus-in-adults?topicKey=RHEUM%2F46 11/22
(IL)-10; B-cell targeted therapy including epratuzumab, tabalumab, atacicept; blisibimod; tolerogens such as
lupuzor and laquinimod; bortezomib; anti-Jak/stat or tyrosine kinases; mizoribine; immunoadsorption, via perfusion
of patients blood through a column of immobilized C1q or polyclonal sheep anti-human immunoglobulin;
recombinant monoclonal antibody that inhibits ligand binding to the human interleukin-6 receptor (tocilizumab);
sirukumab; interleukin-21 antagonist; spliceosomal peptide P140; non-coding (micro)RNA molecules; interferon-
alpha and -gamma inhibitors such as sifalimumab, rontalizumab, AGS 009, and fontolizumab; an anti-TNF
monoclonal antibody (infliximab); AMG-557; and a T-cell costimulation blocker (abatacept) [47,48,120-137].
PROGNOSIS Systemic lupus erythematosus (SLE) can run a varied clinical course, ranging from a relatively
benign illness to a rapidly progressive disease with fulminant organ failure and death. Most patients have a
relapsing and remitting course, which may be associated with the use of high-dose glucocorticoids during the
treatment of severe flares.
Patient survival The five-year survival rate in SLE has dramatically increased since the mid-20th century from
approximately 40 percent in the 1950s to more than 90 percent in studies beginning after 1980 [138-140], a trend
that has continued into the early 21st century [141].
The likelihood of survival can be ranked on the basis of organ involvement (skin and musculoskeletal are best,
central nervous system and kidney are worst) and on the number of American College of Rheumatology criteria for
SLE (table 2) [142]. Older age, male sex, poverty, and a low complement may also be poor prognostic factors, as
was noted in a cohort of North American patients [140]. However, increasing age was not a predictor of an
increased mortality rate in one Chinese cohort of 442 patients when compared with an age-adjusted population
mortality rate [143]. Measures of disease activity and accumulated organ damage may also be predictive of
increased mortality while use of antimalarial drugs may reduce mortality rates [141].
The improvement in patient survival is probably due to multiple factors. These include increased disease recognition
with more sensitive diagnostic tests [144], earlier diagnosis or treatment, the inclusion of milder cases, increasingly
judicious therapy, and prompt treatment of complications [145].
In a 2002 report from the Centers for Disease Control in the United States, deaths due to SLE varied among
different population groups [146]. As examples, the proportion of deaths due to SLE was more than five times
higher in women than men and was more than three times higher in black compared with white women. More than
one-third of deaths due to lupus occurred in people aged 15 to 44 years.
Causes of death The major cause of death in the first few years of illness is active disease (eg, central
nervous system [CNS], renal, or cardiovascular disease) or infection due to immunosuppression, while late deaths
are caused by the illness (eg, end-stage renal disease), by treatment complications (including infection and
coronary disease), by non-Hodgkin lymphoma, and by lung cancer [145,147-151].
The frequency of the different causes of death can be illustrated by the following observations:
The largest study included survival data and causes of death in a total of 9547 patients who were followed for
an average of 8.1 years [151]. Standardized mortality rates (SMR) of SLE patients to expected rates for an
age- and sex-adjusted population were noted for circulatory disease (SMR 1.7), especially heart disease
(SMR 1.7); for non-Hodgkin lymphoma (SMR 2.8); for lung cancer (SMR 19.4); for infections (SMR 9.0),
especially pneumonia (SMR 7.2); and for renal disease (SMR 4.3). Those at particularly high risk for mortality
were younger, female, and black, with disease duration of less than one year.

One study evaluated the causes of death in 408 patients with SLE followed over a mean period of 11 years;
144 (35 percent) died [152]. The major causes of death were active lupus (34 percent), infection (22 percent),
cardiovascular disease (16 percent), and cancer (6 percent). Deaths that resulted directly from SLE and
infection were common among younger patients; the risk of death directly due to SLE was highest in the first
three years after diagnosis.

Another prospective study followed 1000 patients for 10 years [139]. The most frequent causes of death were
28.5.2014 Overview of the therapy and prognosis of systemic lupus erythematosus in adults
http://www.uptodate.com.ezproxy.umf.ro/contents/overview-of-the-therapy-and-prognosis-of-systemic-lupus-erythematosus-in-adults?topicKey=RHEUM%2F46 12/22
Serious infection is most often due to immunosuppressive therapy (see "Secondary immune deficiency induced by
drugs and biologics"). Patients at particular risk are those treated with both glucocorticoids and cyclophosphamide,
especially if the white blood cell count is less than 3000/microL and/or if high-dose glucocorticoids are given
[155,156]. Lymphopenia (<1000/microL) at presentation may be an independent risk factor [157]. (See "General
toxicity of cyclophosphamide and chlorambucil in inflammatory diseases" and "Major side effects of systemic
glucocorticoids".)
Premature coronary artery disease is being increasingly recognized as a cause of late mortality. (See "Coronary
heart disease in systemic lupus erythematosus".)
Is cancer risk increased? Although the relation of SLE to malignancy was previously unclear because
conflicting data [151,158-163], a clear increase of certain malignancies in patients with SLE was subsequently
recognized.
Antimalarial drug use may be associated with a reduced risk of cancer. This is suggested by the results of an
observational study of 235 Spanish patients, among whom two-thirds were treated at some time with an antimalarial
drug while one-third were never treated with one of these agents [171]. After adjustment for other risk factors, use of
antimalarial drugs was associated with a statistically significant (85 percent) reduction in the relative risk of
malignant disease. Further study of the influence of antimalarial drug use on the incidence of cancer did not confirm
these initial results [167]. These agents are used to treat some specific types of organ involvement. (See 'Treatment
of specific organ involvement' above.)
Although some data suggest that the use of immunosuppressive drugs may be associated with the later
development of hematologic malignancies [172], there is insufficient information to conclude whether or not the use
of immunosuppressive medications in patients with SLE increases their risk for malignancies [167].
active SLE (26 percent), infection (25 percent), and thromboses (26 percent) [139].
A cohort of 694 SLE patients were followed longitudinally for 10 years, and the effect of renal disease,
histologic class of lupus nephritis, renal damage and renal failure on the SMR and life expectancy were
reported. The life expectancy of SLE patients with renal disease and those with renal damage was reduced
by 15 years and 24 years, respectively, compared to the general population [153].

In a cohort of 4747 Swedish patients who were diagnosed with SLE between 1964 and 1995, the proportions
of deaths due to cardiovascular events, SLE, and malignant disease were 42 percent, 21 percent, and 12
percent, respectively [154].

An increased risk in patients with SLE, predominantly for that of non-Hodgkin type lymphoma, which was
found in a 2005 meta-analysis [164]. Non-Hodgkin lymphoma in patients with SLE is often an aggressive
histologic subtype, especially diffuse large B-cell lymphoma [165,166].

An association with Hodgkin lymphoma [167]

An increase in lung cancer [167]. Smoking was a predictor for lung cancer in women with SLE.
A twofold increase in the incidence of breast cancer when compared with an age- and gender-matched
segment of the population (standardized incidence ratio of 2.1) [168]

An increase of squamous skin cancer among 238 patients with SLE in Iceland [169]
An increased frequency of abnormal cervical Papanicolaou (Pap) smears in women with SLE [170]. The risk
factors for the development of an abnormal Pap smear include a history of sexually transmitted diseases, the
use of oral contraceptives, and the use of immunosuppressive drugs.

An increased incidence of cervical cancer in one study [162]

An increased risk of vaginal or vulvar cancer, which was seen in one study (RR 5.7) [158]
28.5.2014 Overview of the therapy and prognosis of systemic lupus erythematosus in adults
http://www.uptodate.com.ezproxy.umf.ro/contents/overview-of-the-therapy-and-prognosis-of-systemic-lupus-erythematosus-in-adults?topicKey=RHEUM%2F46 13/22
Prognostic factors Poor prognostic factors for survival in SLE include [139,142,149,152,158,173-179]:
Morbidity Despite a reduction in the risk of premature death, patients with SLE are at risk for significant
morbidity due both to active disease and to the side effects of drugs such as glucocorticoids and cytotoxic agents
[180]. Glucocorticoid-induced avascular necrosis of the hips and knees, osteoporosis, fatigue, and cognitive
dysfunction have become particularly important problems as patients live longer with their illness with a
concomitant increase in total glucocorticoid exposure [181]. (See "Major side effects of systemic glucocorticoids"
and "Prevention and treatment of glucocorticoid-induced osteoporosis".)
Factors that may be associated with a shorter delay between disease onset and organ damage include [182]:
Glucocorticoid use at doses equivalent to prednisone 10 mg/day was associated with a longer time from SLE
onset to organ damage, but, as noted above, long-term use of higher doses of glucocorticoids has significant risks
that must be considered. However, the relationship between glucocorticoid dose and organ damage is not well
defined, and there are conflicting results. A cohort of 525 SLE patients from a single academic medical center was
followed for up to 10 years on varying doses of prednisone, and the findings suggested that low doses of prednisone
do not result in a substantially increased risk of irreversible organ damage [183].
Clinical remission After appropriate therapy, some patients go into a clinical remission, requiring no treatment
[184,185]. The frequency with which this occurs was addressed in two long-term follow-up studies.
In one study of 667 patients, the following were noted [184]:
In a second study of 703 patients, 46 achieved complete clinical remission of at least one-year duration [186].
However, of these, only 12 were still in remission after five years.
These observations demonstrate that remission is uncommon, and, even when achieved, it is frequently not
sustained.
Renal disease (especially diffuse proliferative glomerulonephritis)
Hypertension
Male sex
Young age
Older age at presentation
Poor socioeconomic status
Black race, which may primarily reflect low socioeconomic status
Presence of antiphospholipid antibodies
Antiphospholipid syndrome
High overall disease activity (eg, hemolytic anemia, thrombotic thrombocytopenic purpura [TTP], alveolar
hemorrhage, pulmonary hypertension, mesenteric vasculitis)

Hispanic ethnicity
Greater disease activity
A history of thrombotic events
Glucocorticoid use of less than 10 mg per day
Approximately 25 percent had at least one treatment-free clinical remission lasting for at least one year. The
mean duration of remission was 4.6 years, which represents an underestimate since one-half of the patients
were still in remission at the end of follow-up.

A long history of SLE or the presence of renal or neuropsychiatric disease did not preclude remission.
Among the 48 percent of patients who relapsed after achieving remission, one-half did not achieve a
subsequent remission.

28.5.2014 Overview of the therapy and prognosis of systemic lupus erythematosus in adults
http://www.uptodate.com.ezproxy.umf.ro/contents/overview-of-the-therapy-and-prognosis-of-systemic-lupus-erythematosus-in-adults?topicKey=RHEUM%2F46 14/22
INFORMATION FOR PATIENTS UpToDate offers two types of patient education materials, The Basics and
Beyond the Basics. The Basics patient education pieces are written in plain language, at the 5 to 6 grade
reading level, and they answer the four or five key questions a patient might have about a given condition. These
articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the
Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the
10 to 12 grade reading level and are best for patients who want in-depth information and are comfortable with
some medical jargon.
Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these
topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on
patient info and the keyword(s) of interest.)
SUMMARY AND RECOMMENDATIONS
th th
th th
Basics topic (see "Patient information: Lupus (The Basics)")
Beyond the Basics topics (see "Patient information: Systemic lupus erythematosus (SLE) (Beyond the
Basics)" and "Patient information: Systemic lupus erythematosus and pregnancy (Beyond the Basics)")

An effective therapeutic regimen for the treatment of systemic lupus erythematosus (SLE) first requires the
accurate determination of both disease activity and severity. Disease activity usually refers to the degree of
inflammation, while the degree of severity depends upon the level of organ dysfunction and upon the organs
relative importance. The degree of irreversible organ disfunction has been referred to as the damage index.
Disease activity is assessed using a combination of the clinical history, physical examination, organ-specific
functional tests, and serologic studies. The frequency with which monitoring laboratory tests are performed is
tailored to each patient, generally depending upon the level of disease activity. (See 'Determination of disease
activity and severity' above and 'Clinically useful markers of activity' above and 'Frequency of laboratory testing'
above.)

The pattern and severity of organ involvement determines specific drug therapy, but a number of general
issues are applicable to every patient with SLE. Adherence to medication regimens, maintenance of good
sleep hygiene, and follow-through with recommended testing are of particular importance. Patients should
also be informed of the availability of resource information relating to the treating center and to lupus patient
support organizations. Other important issues include protection from sunlight and from other sources of
ultraviolet light; a balanced approach to diet and nutrition, considering clinical needs; exercise; smoking
cessation; immunizations; treatment of comorbid conditions; avoidance of certain medications; and avoidance
of pregnancy during active disease. (See 'General treatment considerations' above.)

A number of medications are commonly used in the treatment of SLE, including nonsteroidal antiinflammatory
drugs (NSAIDs), antimalarials (primarily hydroxychloroquine), glucocorticoids, and agents that are
immunosuppressive or immunomodulatory (including cyclophosphamide, cyclosporine, tacrolimus,
leflunomide, methotrexate, azathioprine, mycophenolate, and belimumab). Certain drugs are preferred in
selected clinical settings. (See 'Treatment of specific organ involvement' above and 'Other therapies' above.)

Patients with severe organ involvement who are resistant to cyclophosphamide therapy generally do poorly.
The optimal approach to such patients is uncertain. A number of investigational strategies are under
investigation. (See 'Other therapies' above.)

SLE can run a varied clinical course, ranging from a relatively benign illness to a rapidly progressive disease
with fulminant organ failure and death. Most patients have a relapsing and remitting course, which may be
associated with the use of high-dose glucocorticoids during the treatment of severe flares. The five-year
survival rate has improved to greater than 90 percent due to multiple factors. The major cause of death in the
first few years of illness is active disease or infection due to immunosuppression, while causes of late deaths
include the illness, treatment complications, non-Hodgkin lymphoma, and lung cancer. There is an increase in

28.5.2014 Overview of the therapy and prognosis of systemic lupus erythematosus in adults
http://www.uptodate.com.ezproxy.umf.ro/contents/overview-of-the-therapy-and-prognosis-of-systemic-lupus-erythematosus-in-adults?topicKey=RHEUM%2F46 15/22
Use of UpToDate is subject to the Subscription and License Agreement.
Topic 4675 Version 22.0
the frequency of certain malignancies in patients with SLE. (See 'Prognosis' above and 'Patient survival'
above.)
Despite a reduction in the risk of premature death, patients with SLE are at risk for significant morbidity due
both to active disease and to the side effects of drugs such as glucocorticoids and cytotoxic agents. After
appropriate therapy, some patients go into a clinical remission, requiring no treatment. However, remission is
uncommon, and, even when achieved, it is frequently not sustained. (See 'Morbidity' above and 'Clinical
remission' above.)

28.5.2014 Overview of the therapy and prognosis of systemic lupus erythematosus in adults
http://www.uptodate.com.ezproxy.umf.ro/contents/overview-of-the-therapy-and-prognosis-of-systemic-lupus-erythematosus-in-adults?topicKey=RHEUM%2F46 16/22
GRAPHICS
Classification criteria for systemic lupus erythematosus
ACR criteria for the classification of
systemic lupus erythematosus
SLICC criteria for the classification
of systemic lupus erythematosus
(4 of 11 criteria)* (4 of 17 criteria, including at least one clinical
criterion and one immunologic criterion; OR
biopsy-proven lupus nephritis )
Criterion Definition Criterion Definition
Clinical criteria
Malar rash Fixed erythema, flat or
raised, over the malar
eminences, tending to
spare the nasolabial
folds
Acute cutaneous
lupus
Lupus malar rash (do
not count if malar
discoid); bullous lupus;
toxic epidermal
necrolysis variant of
SLE; maculopapular
lupus rash;
photosensitive lupus
rash (in the absence of
dermatomyositis); OR
subacute cutaneous
lupus (nonindurated
psoriaform and/or
annular polycyclic lesions
that resolve without
scarring, although
occasionally with
postinflammatory
dyspigmentation or
telangiectasias)
Photosensitivity Skin rash as a result of
unusual reaction to
sunlight, by patient
history or clinician
observation
Discoid rash Erythematosus raised
patches with adherent
keratotic scaling and
follicular plugging;
atrophic scarring may
occur in older lesions
Chronic
cutaneous lupus
Classic discoid rash;
localized (above the
neck); generalized
(above and below the
neck); hypertrophic
(verrucous) lupus; lupus
panniculitis (profundus);
mucosal lupus; lupus
erythematosus tumidus;
chilblains lupus; OR
discoid lupus/lichen
planus overlap
Nonscarring Diffuse thinning or hair
[1,2] [3]

28.5.2014 Overview of the therapy and prognosis of systemic lupus erythematosus in adults
http://www.uptodate.com.ezproxy.umf.ro/contents/overview-of-the-therapy-and-prognosis-of-systemic-lupus-erythematosus-in-adults?topicKey=RHEUM%2F46 17/22
alopecia fragility with visible
broken hairs (in the
absence of other
causes, such as alopecia
areata, drugs, iron
deficiency, and
androgenic alopecia)
Oral ulcers Oral or nasopharyngeal
ulceration, usually
painless, observed by a
physician
Oral or nasal
ulcers
Palate, buccal, tongue,
OR nasal ulcers (in the
absence of other
causes, such as
vasculitis, Behet's
disease, infection
(herpesvirus),
inflammatory bowel
disease, reactive
arthritis, and acidic
foods)
Arthritis Nonerosive arthritis
involving two or more
peripheral joints,
characterized by
tenderness, swelling, or
effusion
Joint disease Synovitis involving two
or more joints,
characterized by
swelling or effusion OR
Tenderness in two or
more joints and at least
30 minutes of morning
stiffness
Serositis Pleuritis - convincing
history of pleuritic pain
or rubbing heard by
a clinician or evidence of
pleural effusion OR
Serositis Typical pleurisy for more
than one day, pleural
effusions, or pleural rub,
OR
Pericarditis -
documented by EKG,
rub, or evidence of
pericardial effusion
Typical pericardial pain
(pain with recumbency
improved by sitting
forward) for more
than one day, pericardial
effusion, pericardial rub,
or pericarditis by
electrocardiography in
the absence of other
causes, such as
infection, uremia, and
Dressler's syndrome
Renal disorder Persistent proteinuria
greater than 500 mg/24
hours or greater than 3+
if quantitation not
Renal Urine protein-to-
creatinine ratio (or 24-
hour urine protein)
representing 500 mg
28.5.2014 Overview of the therapy and prognosis of systemic lupus erythematosus in adults
http://www.uptodate.com.ezproxy.umf.ro/contents/overview-of-the-therapy-and-prognosis-of-systemic-lupus-erythematosus-in-adults?topicKey=RHEUM%2F46 18/22
performed OR protein/24 hours, OR
Cellular casts - may be
red cell, hemoglobin,
granular, tubular, or
mixed
Red blood cell casts
Neurologic
disorder
Seizures OR psychosis -
in the absence of
offending drugs or
known metabolic
derangements (uremia,
ketoacidosis, or
electrolyte imbalance)
Neurologic Seizures; psychosis;
mononeuritis multiplex
(in the absence of other
known causes, such as
primary vasculitis);
myelitis; peripheral or
cranial neuropathy (in
the absence of other
known causes, such as
primary vasculitis,
infection, and diabetes
mellitus); OR acute
confusional state (in the
absence of other
causes, including
toxic/metabolic, uremia,
drugs)
Hematologic
disorder
Hemolytic anemia - with
reticulocytosis OR
Leukopenia - less than
4000/mm total on two
or more occasions OR
Lymphopenia - less than
1500/mm on two or
more occasions OR
Thrombocytopenia - less
than 100,000/mm (in
the absence of offending
drugs)
Hemolytic anemia Hemolytic anemia
Leukopenia or
lymphopenia
Leukopenia
(<4000/mm at least
once) (in the absence of
other known causes,
such as Felty's
syndrome, drugs, and
portal hypertension), OR
Lymphopenia
(<1000/mm at least
once) (in the absence of
other known causes,
such as glucocorticoids,
drugs, and infection)
Thrombocytopenia Thrombocytopenia
(<100,000/mm ) at
least once in the
absence of other known
causes, such as drugs,
portal hypertension, and
thrombotic
thrombocytopenic
purpura
3
3
3
3
3
3
28.5.2014 Overview of the therapy and prognosis of systemic lupus erythematosus in adults
http://www.uptodate.com.ezproxy.umf.ro/contents/overview-of-the-therapy-and-prognosis-of-systemic-lupus-erythematosus-in-adults?topicKey=RHEUM%2F46 19/22
Immunologic criteria
ANA An abnormal titer of
antinuclear antibody by
immunofluorescence or
an equivalent assay at
any point in time and in
the absence of drugs
known to be associated
with "drug-induced
lupus" syndrome
ANA ANA level above
laboratory reference
range
Immunologic
disorders
Anti-DNA - antibody to
native DNA in abnormal
titer OR
Anti-Sm - presence of
antibody to Sm nuclear
antigen OR
Positive finding of
antiphospholipid
antibody based on an
abnormal serum level of
IgG or IgM anticardiolipin
antibodies, on a positive
test result for lupus
anticoagulant using a
standard method, or on
a false positive serologic
test for syphilis known
to be positive for at
least six months and
confirmed by Treponema
pallidum immobilization
or fluorescent
treponemal antibody
absorption test
Anti-dsDNA Anti-dsDNA antibody
level above laboratory
reference range (or
>twofold the reference
range if tested by ELISA)
Anti-Sm Presence of antibody to
Sm nuclear antigen
Antiphospholipid Antiphospholipid
antibody positivity as
determined by any of
the following: positive
test result for lupus
anticoagulant; false-
positive test result for
rapid plasma reagin;
medium- or high-titer
anticardiolipin antibody
level (IgA, IgG, or IgM);
or positive test result for
anti-beta 2-glycoprotein
I (IgA, IgG, or IgM)
Low complement Low C3; low C4; OR low
CH50
Direct Coombs'
test
Direct Coombs' test in
the absence of hemolytic
anemia
ACR: American College of Rheumatology; SLICC: Systemic Lupus International Collaborating Clinics;
SLE: systemic lupus erythematosus; EKG: electrocardiogram; ANA: antinuclear antibodies; anti-
dsDNA: anti-double-stranded DNA; ELISA: enzyme-linked immunosorbent assay; Anti-Sm: anti-
Smith antibody; IgA: immunoglobulin A; IgG: immunoglobulin G; IgM: immunoglobulin M.
28.5.2014 Overview of the therapy and prognosis of systemic lupus erythematosus in adults
http://www.uptodate.com.ezproxy.umf.ro/contents/overview-of-the-therapy-and-prognosis-of-systemic-lupus-erythematosus-in-adults?topicKey=RHEUM%2F46 20/22
* For the ACR criteria, no distinction is made between clinical and immunologic criteria in
determining whether the required number has been met. The classification is based upon 11
criteria. For the purpose of identifying patients in clinical studies, a person is said to have systemic
lupus erythematosus if any 4 or more of the 11 criteria are present, serially or simultaneously,
during any interval of observation.
For the SLICC criteria, criteria are cumulative and need not be presently concurrently. A patient is
classified as having SLE if he or she satisfies four of the clinical and immunologic criteria used in the
SLICC classification criteria, including at least one clinical criterion and one immunologic criterion.
Alternatively, according to the SLICC criteria, a patient is classified as having SLE if he or she has
biopsy-proven nephritis compatible with SLE in the presence of ANAs or anti-dsDNA antibodies.
References:
1. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic
lupus erythematosus. Arthritis Rheum 1982; 25:1271.
2. Hochberg MC. Updating the American College of Rheumatology revised criteria for the
classification of systemic lupus erythematosus (letter). Arthritis Rheum 1997; 40:1725.
3. Petri M, Orbai AM, Alarcn GS, et al. Derivation and validation of the Systemic Lupus International
Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum
2012; 64:2677.
Graphic 86633 Version 3.0
28.5.2014 Overview of the therapy and prognosis of systemic lupus erythematosus in adults
http://www.uptodate.com.ezproxy.umf.ro/contents/overview-of-the-therapy-and-prognosis-of-systemic-lupus-erythematosus-in-adults?topicKey=RHEUM%2F46 21/22
ACR criteria for the classification of systemic lupus erythematosus
Criterion Definition
Malar rash Fixed erythema, flat or raised, over the malar eminences, tending to spare
the nasolabial folds
Discoid rash Erythematosus raised patches with adherent keratotic scaling and follicular
plugging; atrophic scarring may occur in older lesions
Photosensitivity Skin rash as a result of unusual reaction to sunlight, by patient history
or clinician observation
Oral ulcers Oral or nasopharyngeal ulceration, usually painless, observed by a clinician
Arthritis Nonerosive arthritis involving two or more peripheral joints, characterized
by tenderness, swelling, or effusion
Serositis Pleuritis - Convincing history of pleuritic pain or rub heard by a clinician or
evidence of pleural effusion OR
Pericarditis - Documented by EKG, rub, or evidence of pericardial effusion
Renal disorder Persistent proteinuria greater than 0.5 grams per day or greater than 3+ if
quantitation not performed OR
Cellular casts - May be red cell, hemoglobin, granular, tubular, or mixed
Neurologic
disorder
Seizures OR psychosis - In the absence of offending drugs or known
metabolic derangements (uremia, ketoacidosis, or electrolyte imbalance)
Hematologic
disorder
Hemolytic anemia - With reticulocytosis OR
Leukopenia - Less than 4000/mm total on two or more occasions OR
Lymphopenia - Less than 1500/mm on two or more occasions OR
Thrombocytopenia - Less than 100,000/mm in the absence of offending
drugs
Immunologic
disorders
Anti-DNA - Antibody to native DNA in abnormal titer OR
Anti-Sm - Presence of antibody to Sm nuclear antigen OR
Positive antiphospholipid antibody on:
1. An abnormal serum level of IgG or IgM anticardiolipin antibodies, or
2. A positive test result for lupus anticoagulant using a standard method,
or
3. A false-positive test result for at least six months confirmed by
Treponema pallidum immobilization or fluorescent treponemal antibody
absorption test
Antinuclear
antibody
An abnormal titer of antinuclear antibody by immunofluorescence or an
equivalent assay at any point in time and in the absence of drugs known to
be associated with "drug-induced lupus" syndrome
ACR: American College of Rheumatology; EKG: electrocardiogram; IgG: immunoglobulin G; IgM:
immunoglobulin M.
3
3
3
28.5.2014 Overview of the therapy and prognosis of systemic lupus erythematosus in adults
http://www.uptodate.com.ezproxy.umf.ro/contents/overview-of-the-therapy-and-prognosis-of-systemic-lupus-erythematosus-in-adults?topicKey=RHEUM%2F46 22/22
Graphic 73334 Version 5.0